RCE News: Recce Pharmaceuticals Announces Phase I Clinical Trial of RECCE® 327 Advances to High Dosing Leve - 13th Apr 2022, 10:00pm

annb0t

Top 20
Recce Pharmaceuticals

Dose increase of R327 Dose increase of R327

Highlights:

36 subjects successfully dosed in Phase I intravenous (IV) clinical trial of RECCE® 327 (R327) – demonstrating good safety and tolerability at 1,000mg Independent Safety Committee affirms ‘low-dose’ cohort clinical trial complete, endpoints achieved – recommends ‘high dose’ cohort dosing to begin Committee clears cohort five (R327 – 2,000mg IV) dosing – subjects recruited ...

>>> Read more: Recce Pharmaceuticals Announces Phase I Clinical Trial of RECCE® 327 Advances to High Dosing Level
 
Top Bottom